Molecular pathology of thymoma and thymic carcinoma

Abstract

Thymic epithelial tumors (TETs) comprise a heterogeneous group of epithelial-derived thymic neoplasms with diverse clinical behavior and underlying molecular genetic features. Owing to their rare nature, the molecular classification of TETs has only recently begun to be fully explored. The advent of advanced molecular studies, particularly the ability to sequence the DNA and RNA of tumors in a massively parallel fashion, has led to an increased understanding of the molecular underpinnings of thymic neoplasia. Thymomas, characterized by a heterogeneous group of molecular alterations, tend to have low mutational burdens and various copy number abnormalities including a characteristic loss of chromosomal material in the region of 6q25.2-p25.3, a recurrent, specific point mutation GTF2I p.L424H, and specific expression of certain microRNAs. Thymic carcinomas, in contrast, are generally characterized by increased tumor mutational burdens, multiple copy number alterations, and varied, non-recurrent, somatic mutations. Advances in molecular knowledge of TETs allow for more precise molecular classification of these tumors, and the presence of specific alterations aids in the diagnosis of borderline lesions. In the future, additional molecular studies will better delineate the molecular landscape of these tumors and may one day allow for more targeted treatment algorithms. This review aims to cover the current understanding of the molecular alterations thus far identified in thymomas and thymic carcinomas.

Keywords

Thymoma / thymic carcinoma / GTF2I / molecular / genetics

References

[1] WHO. Classification of tumors editorial board. Thoracic tumours, 5th ed.; vol. 5. Lyon: IARC Press; 2021.

[2] Engels EA.Epidemiology of thymoma and associated malignancies.J Thorac Oncol2010;5:S260-5 PMCID:PMC2951303

[3] Suster D,Suster S. Diagnostic pathology: thoracic, 5th ed.; Philadelphia, PA: Eslevier; 2022.

[4] Detterbeck FC,Giroux D.The IASLC/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.J Thorac Oncol2014;9:S65-72

[5] Filosso PL,Lausi PO.Historical perspectives: the evolution of the thymic epithelial tumors staging system.Lung Cancer2014;83:126-32

[6] Weissferdt A,Bishop JA.Thymoma: a clinicopathological correlation of 1470 cases.Hum Pathol2018;73:7-15

[7] Roden AC,Jenkins SM.Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis.Am J Surg Pathol2015;39:427-41

[8] Moran CA,Suster S.Thymomas II: a clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment.Am J Clin Pathol2012;137:451-61

[9] Suster S.Problem areas and inconsistencies in the WHO classification of thymoma.Semin Diagn Pathol2005;22:188-97

[10] Detterbeck FC. Thymus. In: Amin MB, Greene FL, Edge SB, et al., editors. AJCC Cancer Staging Manual. Chicago, IL: Springer; 2017. p. 423-29.

[11] Koga K,Noguchi M.A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma.Pathol Int1994;44:359-67

[12] Masaoka A,Nakahara K.Follow-up study of thymomas with special reference to their clinical stages.Cancer1981;48:2485-92

[13] Verghese ET,Campbell A.Interobserver variation in the classification of thymic tumours--a multicentre study using the WHO classification system.Histopathology2008;53:218-23

[14] Hsu CH,Yin CH,Chern CU.Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States.PLoS ONE2019;14:e0227197 PMCID:PMC6938371

[15] Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy.Eur J Cancer2008;44:123-30

[16] Weis CA,Deng Y.Contributors to the ITMIG Retrospective DatabaseThe impact of thymoma histotype on prognosis in a worldwide database.J Thorac Oncol2015;10:367-72 PMCID:PMC4318643

[17] Marx A,Leite MI.Thymoma and paraneoplastic myasthenia gravis.Autoimmunity2010;43:413-27

[18] Zaman M,Buckland M.Clinical and laboratory features of seventy-eight UK patients with Good's syndrome (thymoma and hypogammaglobulinaemia).Clin Exp Immunol2019;195:132-8 PMCID:PMC6300645

[19] Kisand K,Podkrajsek KT.Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines.J Exp Med2010;207:299-308 PMCID:PMC2822605

[20] Christopoulos P,Malkovsky M.A novel thymoma-associated immunodeficiency with increased naive T cells and reduced CD247 expression.J Immunol2015;194:3045-53

[21] Inoue M,Zettl A.Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas.Cancer Res2003;63:3708-15

[22] Penzel R,Schmitz W.Clusters of chromosomal imbalances in thymic epithelial tumours are associated with the WHO classification and the staging system according to Masaoka.Int J Cancer2003;105:494-8

[23] Petrini I,Pham T.Whole genome and transcriptome sequencing of a B3 thymoma.PLoS ONE2013;8:e60572 PMCID:PMC3618227

[24] Petrini I,Zucali PA.Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.Cell Death Dis2012;3:e351 PMCID:PMC3406591

[25] Petrini I,Zucali PA.Copy number aberrations of genes regulating normal thymus development in thymic epithelial tumors.Clin Cancer Res2013;19:1960-71 PMCID:PMC3630263

[26] Cin P, De Wolf-peeters C, Deneffe G, Fryns J, Van den Berghe H. Thymoma with a t(15;22)(p11;q11).Cancer Genet Cytogenet1996;89:181-3

[27] Zettl A,Wagner K.Recurrent genetic aberrations in thymoma and thymic carcinoma.Am J Pathol2000;157:257-66 PMCID:PMC1850202

[28] Kristoffersson U,Mandahl N,Mitelman F.Multiple clonal chromosome aberrations in two thymomas.Cancer Genet Cytogenet1989;41:93-8

[29] Mirza I,Ligi R,Braza F.Cytogenetic profile of a thymoma. A case report and review of the literature.Arch Pathol Lab Med2000;124:1714-6

[30] den Berghe I, Debiec-rychter M, Proot L, Hagemeijer A, Michielssen P. Ring chromosome 6 may represent a cytogenetic subgroup in benign thymoma.Cancer Genet Cytogenet2002;137:75-7

[31] Lee GY,Jeung HC.Genome-wide genetic aberrations of thymoma using cDNA microarray based comparative genomic hybridization.BMC Genomics2007;8:305 PMCID:PMC2082448

[32] Girard N,Guo T.Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.Clin Cancer Res2009;15:6790-9 PMCID:PMC2783876

[33] Enkner F,Zaharie AT.Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets.Pathol Oncol Res2017;23:551-64 PMCID:PMC5487866

[34] Radovich M,Hancock BA.A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.Br J Cancer2016;114:477-84 PMCID:PMC4815766

[35] Petrini I,Kim IK.A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.Nat Genet2014;46:844-9 PMCID:PMC5705185

[36] Feng Y,Wu X.GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis.Lung Cancer2017;110:48-52

[37] Radovich M,Felau I.Cancer genome atlas networkthe integrated genomic landscape of thymic epithelial tumors.Cancer Cell2018;33:244-258.e10 PMCID:PMC5994906

[38] Vivero M,Nardi V,Sholl LM.Metaplastic thymoma: a distinctive thymic neoplasm characterized by YAP1-MAML2 gene fusions.Mod Pathol2020;33:560-5

[39] Zhao J,Xiang C,Guo L..YAP1-MAML211:692283 PMCID:PMC8329546

[40] Massoth LR,Dias-Santagata D.Pan-Cancer landscape analysis reveals recurrent.KMT2A4:PO.19.00288 PMCID:PMC7446345

[41] Sonobe H,Nakayama H,Nishiya K.A thymic squamous cell carcinoma with complex chromosome abnormalities.Cancer Genet Cytogenet1998;103:83-5

[42] Yuan X,Luo W.Diagnostic and prognostic significances of SOX9 in thymic epithelial tumor.Front Oncol2021;11:708735 PMCID:PMC8580949

[43] Wang Y,Lau C.Mutations of epigenetic regulatory genes are common in thymic carcinomas.Sci Rep2014;4:7336 PMCID:PMC4258655

[44] Kishibuchi R,Soejima S.DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma.Int J Oncol2020;56:315-26

[45] Yoh K,Ishii G.Mutational status of EGFR and KIT in thymoma and thymic carcinoma.Lung Cancer2008;62:316-20

[46] Tsuchida M,Hashimoto T.Absence of gene mutations in KIT-positive thymic epithelial tumors.Lung Cancer2008;62:321-5

[47] Petrini I,Lee HS.Expression and mutational status of c-kit in thymic epithelial tumors.J Thorac Oncol2010;5:1447-53 PMCID:PMC7328988

[48] Hirabayashi H,Sakaguchi M.p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation ofCDKN2 gene in thymoma and thymic carcinoma.Int J Cancer1997;73:639-44

[49] Tateyama H,Tada T.p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study.Am J Clin Pathol1995;104:375-81

[50] Sakane T,Okuda K.A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.Histopathology2019;75:755-66

[51] Hsueh C,Tsang NM,Yang CP.Thymic lymphoepitheliomalike carcinoma in children: clinicopathologic features and molecular analysis.J Pediatr Hematol Oncol2006;28:785-90

[52] Chen PC,Yang AH,Chiang H.Detection of Epstein-Barr virus genome within thymic epithelial tumours in Taiwanese patients by nested PCR, PCR in situ hybridization, and RNA in situ hybridization.J Pathol2002;197:684-8

[53] Suster D,Mackinnon AC.Poorly Differentiated nonkeratinizing squamous cell carcinoma of the thymus: clinicopathologic and molecular genetic study of 25 cases.Am J Surg Pathol2018;42:1224-36

[54] Suster D,Mackinnon AC.Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus.Mod Pathol2018;31:1801-6

[55] Sakanoue I,Fujimoto D..KRAS9:E694-7 PMCID:PMC5594120

[56] Lee Y,Lee SH.Characterization of genetic aberrations in a single case of metastatic thymic adenocarcinoma.BMC Cancer2017;17:330 PMCID:PMC5432996

[57] Maghbool M,Nagel I.Primary adenocarcinoma of the thymus: an immunohistochemical and molecular study with review of the literature.BMC Clin Pathol2013;13:17 PMCID:PMC3672093

[58] Eimoto T,Ogawa H.Thymic sarcomatoid carcinoma with skeletal muscle differentiation: report of two cases, one with cytogenetic analysis.Histopathology2002;40:46-57

[59] Porubsky S,Kee D.Potentially actionable FGFR2 high-level amplification in thymic sebaceous carcinoma.Virchows Arch2020;476:323-7

[60] Porubsky S,Rückert JC.International Thymic Malignancy Interest Group (ITMIG)EWSR1 translocation in primary hyalinising clear cell carcinoma of the thymus.Histopathology2019;75:431-6

[61] Roden AC,Yi ES.Analysis of MAML2 rearrangement in mucoepidermoid carcinoma of the thymus.Hum Pathol2013;44:2799-805

[62] Prieto-Granada CN,Mueller J.Thymic mucoepidermoid carcinoma: report of a case with CTRC1/3-MALM2 molecular studies.Int J Surg Pathol2015;23:277-83

[63] Evans AG,Cameron MJ.Pathologic characteristics of NUT midline carcinoma arising in the mediastinum.Am J Surg Pathol2012;36:1222-7 PMCID:PMC3396884

[64] Gökmen-Polar Y,Loehrer PJ Sr.NUT midline carcinoma masquerading as a thymic carcinoma.J Clin Oncol2016;34:e126-9

[65] Gökmen-Polar Y,Kesler KA,Badve S.NUT midline carcinomas in the thymic region.Mod Pathol2014;27:1649-56

[66] French CA,Kubonishi I.BRD₄-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.Cancer Res2003;63:304-7.

[67] French CA,Kolmakova J.BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.Oncogene2008;27:2237-42

[68] Shiota H,Alekseyenko AA.“Z4” Complex member fusions in NUT carcinoma: implications for a novel oncogenic mechanism.Mol Cancer Res2018;16:1826-33 PMCID:PMC6279489

[69] Alekseyenko AA,Zee BM.Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.Proc Natl Acad Sci USA2017;114:E4184-92 PMCID:PMC5448232

[70] French CA,Walsh EM.NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.Cancer Discov2014;4:928-41 PMCID:PMC4125436

[71] Suster DI,DiStasio M,Pihan G.Atypical thymomas with squamoid and spindle cell features: clinicopathologic, immunohistochemical and molecular genetic study of 120 cases with long-term follow-up.Mod Pathol2022;

[72] Hamaji M,Burt BM.A meta-analysis of induction therapy for advanced thymic epithelial tumors.Ann Thorac Surg2015;99:1848-56

[73] Sato J,Itoh S.Lenvatinib in patients with advanced or metastatic thymic carcinoma(REMORA): a multicentre, phase 2 trial.Lancet Oncol2020;21:843-50

[74] Wheler J,Swisher SG.Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses.Oncotarget2013;4:890-8 PMCID:PMC3757246

[75] Giaccone G,Thompson J.Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.Lancet Oncol2018;19:347-55

[76] Katsuya Y,Seto T.Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.Eur J Cancer2019;113:78-86

[77] McLeod C,Zhou X.St. Jude cloud: a pediatric cancer genomic data-sharing ecosystem.Cancer Discov2021;11:1082-99 PMCID:PMC8102307

[78] Edmonson MN,Hedges DJ.Pediatric Cancer Variant Pathogenicity Information Exchange (PeCanPIE): a cloud-based platform for curating and classifying germline variants.Genome Res2019;29:1555-65 PMCID:PMC6724669

[79] Zhou X,Patel J.Exploration of coding and non-coding variants in cancer using genomepaint.Cancer Cell2021;39:83-95.e4 PMCID:PMC7884056

[80] Di Tommaso L,Kurrer M.Thymic tumor with adenoid cystic carcinomalike features: a clinicopathologic study of 4 cases.Am J Surg Pathol2007;31:1161-7